These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3669166)

  • 1. Vasoactive intracavernous pharmacotherapy--the nursing role in teaching self-injection therapy.
    Duffy LM; Sidi AA; Lange PH
    J Urol; 1987 Nov; 138(5):1198-200. PubMed ID: 3669166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence.
    Sidi AA; Reddy PK; Chen KK
    J Urol; 1988 Aug; 140(2):293-4. PubMed ID: 3294441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Teaching the patient about intra-cavernous injections to prevent erectile dysfunction].
    Héron M
    Soins; 2007 Mar; (713):50-1. PubMed ID: 17419575
    [No Abstract]   [Full Text] [Related]  

  • 4. Compliance to longterm vasoactive intracavernous therapy.
    Pagliarulo A; Ludovico GM; Cirillo-Marucco E; Corvasce A; Pagliarulo G
    Int J Impot Res; 1996 Jun; 8(2):63-4. PubMed ID: 8858392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Import catheter in erectile dysfunction.
    Kayigil O; Atahan O; Metin A
    J Urol; 1997 Aug; 158(2):530-2. PubMed ID: 9224341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernosal injection therapy: a practical guide.
    Mulhall JP
    Tech Urol; 1997; 3(3):129-34. PubMed ID: 9422443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
    Polito M; d'Anzeo G; Conti A; Muzzonigro G
    BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intracavernous pharmacotherapy.
    Sidi AA
    Urol Clin North Am; 1988 Feb; 15(1):95-101. PubMed ID: 2449756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence.
    Zorgniotti AW; Lefleur RS
    J Urol; 1985 Jan; 133(1):39-41. PubMed ID: 2578067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intracavernous injection of vasoactive agents].
    Kawanishi Y
    Nihon Rinsho; 2002 Jun; 60 Suppl 6():285-9. PubMed ID: 12166159
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
    Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
    Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy.
    Kim SC; Seo KK; Park BD; Lee SW
    Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs.
    Watters GR; Keogh EJ; Earle CM; Carati CJ; Wisniewski ZS; Tulloch AG; Lord DJ
    J Urol; 1988 Dec; 140(6):1417-9. PubMed ID: 3193507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracavernous injection of papaverine, phentolamine and phenoxybenzamine.
    Pettirossi O; Serenelli G
    Acta Urol Belg; 1988; 56(2):211-9. PubMed ID: 3400527
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound.
    Yang Y; Hu JL; Ma Y; Wang HX; Chen Z; Xia JG; Wang YX; Huang YR; Chen B
    J Urol; 2011 Jul; 186(1):228-32. PubMed ID: 21575959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group.
    Giuliano F; Montorsi F; Mirone V; Rossi D; Sweeney M
    J Urol; 2000 Sep; 164(3 Pt 1):708-11. PubMed ID: 10953130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective study on the incidence and cause of drop-out during intracavernous pharmaco-prosthesis therapy].
    Giammusso B; Motta M
    Arch Ital Urol Androl; 2002 Mar; 74(1):27-31. PubMed ID: 12053447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow up outcome of intracavernous papaverine.
    al-Juburi AZ; O'Donnell PD
    J Ark Med Soc; 1990 Mar; 86(10):383-5. PubMed ID: 2138146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.